Hematopoietic Growth Factors: 2026 ASCO Guidance, Mechanisms and Safety

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment.

Overview

Hematopoietic growth factors support production of blood-cell lineages or mobilization of hematopoietic progenitors. Treatment must match the underlying condition: neutropenia, anemia, thrombocytopenia and stem-cell collection have different agents, goals and harms [1,2].

Classes and receptor mechanisms

  • G-CSF: filgrastim, pegfilgrastim and biosimilars stimulate G-CSF receptors on neutrophil precursors; signaling involves JAK/STAT, PI3K and MAPK pathways.
  • GM-CSF: sargramostim promotes several myeloid lineages, with indications distinct from G-CSF.
  • Erythropoiesis-stimulating agents (ESAs): epoetin alfa and darbepoetin alfa activate erythropoietin receptors to sustain erythroid progenitors; darbepoetin’s longer action results from additional glycosylation, not PEGylation.
  • Thrombopoietin-receptor agonists: romiplostim (peptibody), eltrombopag and avatrombopag stimulate MPL signaling and platelet production for specific thrombocytopenic conditions; these are not all recombinant proteins.
  • Stem-cell mobilization: CXCR4 antagonists such as plerixafor can be combined with G-CSF in selected protocols [1,2].

ASCO white-blood-cell growth factor recommendations in 2026

ASCO’s 2026 update recommends primary G-CSF prophylaxis when the chemotherapy regimen’s febrile-neutropenia risk is approximately 20% or greater and an equally effective safer regimen without growth factor is unavailable. With lower-risk regimens, patient-related factors such as age, comorbidities and disease may justify prophylaxis. G-CSF can support stem-cell mobilization alone, after chemotherapy, or with approved mobilization drugs, under specialist protocols [2].

Erythropoiesis-stimulating drugs

ESAs may be used for selected chronic kidney disease–associated anemia and certain chemotherapy-associated anemias. They increase hemoglobin but can cause hypertension, thrombosis, stroke and other risks when targets are overly aggressive. They should not be given simply to normalize hemoglobin in all patients; assess iron deficiency, inflammatory disease and the patient’s clinical context. ESA use in cancer requires adherence to oncology-specific indications and safety warnings [1].

TPO agonists and severe refractory conditions

Romiplostim and eltrombopag are used in selected immune thrombocytopenia conditions; eltrombopag is also used in certain aplastic anemia regimens. Liver toxicity, marrow changes and thrombotic risk require monitoring. Avoid presenting TPO agonists as treatment for all low platelet counts or routine COVID-associated thrombocytopenia [1].

Adverse effects and clinical monitoring

G-CSF can cause bone pain, leukocytosis and rare splenic rupture or acute respiratory complications. Sargramostim may cause fever, capillary leak and fluid retention. ESAs require hemoglobin and blood-pressure monitoring; TPO agonists require platelet, liver-function and thrombosis-risk review. Filgrastim and pegfilgrastim are not dosed interchangeably; administration timing relative to myelosuppressive chemotherapy follows product-specific protocols [1,2].

Practical conclusion

Use guideline-based risk assessment rather than automatically prescribing a colony-stimulating factor after every chemotherapy cycle. Reassess response and harms, and separate blood-cell production support from definitive treatment of underlying marrow pathology [2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. American Society of Clinical Oncology. White blood cell growth factors: ASCO guideline update. J Clin Oncol. 2026. doi:10.1200/JCO-25-02938. Available from: https://doi.org/10.1200/JCO-25-02938
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *